NASDAQ:BDRX - US59564R8079 - ADR
The current stock price of BDRX is 6.59 USD. In the past month the price decreased by -25.11%. In the past year, price decreased by -95.78%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.89 | 372.00B | ||
AMGN | AMGEN INC | 13.47 | 157.94B | ||
GILD | GILEAD SCIENCES INC | 14.83 | 142.77B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 101.47B | ||
REGN | REGENERON PHARMACEUTICALS | 12.92 | 63.65B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
ARGX | ARGENX SE - ADR | 71.2 | 40.39B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.78 | 33.95B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
INSM | INSMED INC | N/A | 25.02B | ||
NTRA | NATERA INC | N/A | 22.61B | ||
BIIB | BIOGEN INC | 8.7 | 20.41B |
Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 13 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
BIODEXA PHARMACEUTICALS-ADR
1 Caspian Point, Caspian Way
Abingdon OXFORDSHIRE GB
Employees: 13
Phone: 4401235888300
The current stock price of BDRX is 6.59 USD. The price decreased by -2.37% in the last trading session.
The exchange symbol of BIODEXA PHARMACEUTICALS-ADR is BDRX and it is listed on the Nasdaq exchange.
BDRX stock is listed on the Nasdaq exchange.
7 analysts have analysed BDRX and the average price target is 183.6 USD. This implies a price increase of 2686.04% is expected in the next year compared to the current price of 6.59. Check the BIODEXA PHARMACEUTICALS-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIODEXA PHARMACEUTICALS-ADR (BDRX) has a market capitalization of 19.05M USD. This makes BDRX a Nano Cap stock.
BIODEXA PHARMACEUTICALS-ADR (BDRX) currently has 13 employees.
BIODEXA PHARMACEUTICALS-ADR (BDRX) has a resistance level at 6.62. Check the full technical report for a detailed analysis of BDRX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BDRX does not pay a dividend.
BIODEXA PHARMACEUTICALS-ADR (BDRX) will report earnings on 2025-09-22.
BIODEXA PHARMACEUTICALS-ADR (BDRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.43).
ChartMill assigns a fundamental rating of 1 / 10 to BDRX. BDRX has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months BDRX reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 99.7% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -38.76% | ||
ROE | -68.84% | ||
Debt/Equity | 0.07 |
7 analysts have analysed BDRX and the average price target is 183.6 USD. This implies a price increase of 2686.04% is expected in the next year compared to the current price of 6.59.